Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase

Oncotarget

Volumn 7, Issue 40, 2016, Pages 65732-65743

  Song, Xinhua ^a   Yin, Shutao ^a   Zhang, Enxiang ^a   Fan, Lihong ^a   Ye, Min ^b   Zhang, Yong ^c   Hu, Hongbo ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Anti liver cancer; Glycycoumarin; Licorice; P53; T LAK cell originated protein kinase

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCYCOUMARIN; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; T LAK CELL ORIGINATED PROTEIN KINASE; UNCLASSIFIED DRUG; COUMARIN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDZ-BINDING KINASE; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; LIVER TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN CONFORMATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; COUMARINS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTEIN CONFORMATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994121586     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11610     Document Type: Article

References (31)

1. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099-2108.
2. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012;3:236-260. doi: 10.18632/oncotarget.466.
3. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424.
4. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006;66:9186-9195.
5. Zhu F, Zykova TA, Kang BS, Wang Z, Ebeling MC, Abe Y, Ma WY, Bode AM, Dong Z. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology. 2007;133:219-231.
6. Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, Lai JM. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene. 2012;31:2389-2400.
7. Chen F, Li R, Wang C, Cao L, Wang Y, Yu L. T-LAK celloriginated protein kinase is essential for the proliferation of hepatocellular carcinoma SMMC-7721 cells. Cell Biochem Funct. 2013;31:736-742.
8. Kim DJ, Li Y, Reddy K, Lee MH, Kim MO, Cho YY, Lee SY, Kim JE, Bode AM, Dong Z. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res. 2012;72:3060-3068
9. Matsuo Y, Park JH, Miyamoto T, Yamamoto S, Hisada S, Alachkar H, Nakamura Y. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014;6:259ra145.
10. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer. 2001;39:1-11. Review
11. Zhang Q and Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J Chromatogr A. 2009;1216:1954-1969.
12. Asl, M.N. and H. Hosseinzadeh. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22:709-724.
13. Qiao X, Liu CF, Ji S, Lin XH, Guo DA, Ye M. Simultaneous determination of five minor coumarins and flavonoids in Glycyrrhiza uralensis by solid-phase extraction and high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Planta Med 2014;80:237-242.
14. Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, Chen CH, Suda G, Mishima K, Onuki Y, Yamamoto M, Maekawa S, Enomoto N, et al. Two flavonoids extracts from Glycyrrhizae radix inhibit in vitro hepatitis C virus replication. Hepatol Res 2009;39:60-69.
15. Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Soetjipto, Fuchino H, Kawahara N, Hotta H. Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. Microbiol Immunol 2014;58:180-187.
16. Fu Y, Chen J, Li Y, Zheng Y, Li P. Antioxidant and antiinflammatory activities of six flavonoids separated from licorice. Food Chem 2013;141:1063-1071.
17. Lee KK, Omiya Y, Yuzurihara M, Kase Y, Kobayashi H. Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: role of the active constituents of Glycyrrhizae radix. J Ethnopharmacol 2013;146:431.
18. Song X, Yin S, Huo Y, Liang M, Fan L, Ye M, Hu H. Glycycoumarin ameliorates alcohol-induced hepatotoxicity via activation of Nrf2 and autophagy. Free Radic Biol Med. 2015;89:135-146.
19. Hu F, Gartenhaus RB, Eichberg D, Liu Z, Fang HB, Rapoport AP. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene. 2010;29:5464-5474.
20. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS and Olson AJ. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J Comput Chem. 2009; 30: 2785-2791.
21. Trott O and Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31: 455-461.
22. Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells. Mol Cancer Ther. 2007;6:1588-1598.
23. Roohbakhsh A, Iranshahy M, Iranshahi M. Glycyrrhetinic acid and its derivatives: Anti-cancer and cancer chemopreventive properties, mechanisms of action and structure-cytotoxic activity relationship. Curr Med Chem. 2016 Jan 12. [Epub ahead of print].
24. Lee E, Son JE, Byun S, Lee SJ, Kim YA, Liu K, Kim J, Lim SS, Park JH, Dong Z, Lee KW, Lee HJ. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol Appl Pharmacol. 2013;272:12-20.
25. Song NR, Lee E, Byun S, Kim JE, Mottamal M, Park JH, Lim SS, Bode AM, Lee HJ, Lee KW, Dong Z Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma. Cancer Prev Res (Phila). 2013;6:1293-1303.
26. Huang W, Tang S, Qiao X, Ma W, Ji S, Wang K, Ye M, Yu S. Isoangustone A induces apoptosis in SW480 human colorectal adenocarcinoma cells by disrupting mitochondrial functions. Fitoterapia. 2014;94:36-47.
27. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D, Brown PO. Gene expression patterns in human liver cancers. Mol. Biol. Cell. 2002: 13:1929-1939.
28. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-660.
29. Källberg M, Wang H, Wang S, Peng J, Wang Z, Lu H and Xu J. Template-based protein structure modeling using the RaptorX web server. Nature Protocols. 2012; 7:1511-1522.
30. Yang J, Yan R, Roy A, Xu D, Poisson J and Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12:7-8.
31. Raman S, Vernon R, Thompson J, Tyka M, Sadreyev R, Pei J, Kim D, Kellogg E, DiMaio F, Lange O, Kinch L, Sheffler W, Kim BH, Das R, Grishin NV and Baker D. Structure prediction for CASP8 with all-atom refinement using Rosetta. Proteins. 2009; 77: 89-99.